Vascular endothelial growth factor can increase vascular permeability and promote neovascularization, playing an important role in the pathogenesis of diabetic retinopathy. At present, its monotherapy or combination therapy have been widely used in the clinical treatment of diabetic retinopathy, especially diabetic macular edema, neovascular glaucoma and vitreous hemorrhage. In this paper, the points mentioned above will beare systematically reviewed.
赵敏婕,郑志. 抗血管内皮生长因子药物治疗糖尿病视网膜病变的研究进展[J]. 中华眼视光学与视觉科学杂志, 2016, 18(9): 573-576.
Zhao Minjie,Zheng Zhi. Research progress on drugs used for the anti-vascular endothelial growth factor drugs in the treatment of diabetic retinopathy. Chinese Journal of Optometry Ophthalmology and Visual science, 2016, 18(9): 573-576. DOI: DOI:10.3760/cma.j.issn.1674-845X.2016.09.016
Zhang X, Bao S, Hambly BD, et al. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy[J]. Int J Biochem Cell Biol,2009,41(12):2368-2371. DOI:10.1016/j.biocel.2009.07.011.
Abdallah W, Fawzi AA. Anti-VEGF therapy in proliferative diabetic retinopathy[J]. Int Ophthalmol Clin,2009,49(2):95-107. DOI:10.1097/110.0b013e31819fd84a.
[4]
Stewart MW, Grippon S, Kirkpatrick P. Aflibercept[J]. Nat Rev Drug Discov,2012,11(4):269-270. DOI:10.1038/nrd3700.
[5]
Singerman L. Combination therapy using the small interfering RNA bevasiranib[J]. Retina,2009,29(6 suppl):S49-50. DOI:10.1097/IAE.0b013e3181ad2341.
[6]
Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study[J]. Ophthalmology,2014,121(9):1740-1247. DOI:10.1016/j.ophtha.2014. 03.026.
[7]
Shin YW, Lee YJ, Lee BR, et al. Effects of an Intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy[J]. Korean J Ophthalmol,2009,23(4):266-272. DOI:10.3341/kjo.2009.23.4.266.
[8]
Messias A, Ramos Filho JA, Messias K, et al. Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy[J]. Doc Ophthalmol,2012,124(3):225-236. DOI:10.1007/s10633-012-9322-5.
[9]
Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy[J]. Acta Ophthalmol,2011,89(7):e567-572. DOI:10.1111/j.1755-3768.2011.02184.x.
[10]
Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial[J]. Ophthalmology,2009,116(10):1943-1948. DOI:10.1016/j.ophtha.2009.07.001.
[11]
Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J]. Cochrane Database Syst Rev,2015(8):CD008214. DOI:10.1002/14651858.CD008214.pub3.
[12]
Zhang ZH, Liu HY, Hernandez-Da Mota SE, et al. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials[J]. Am J Ophthalmol,2013,156(1):106-115. e2. DOI:10.1016/j.ajo.2013.02.008.
[13]
El-Sabagh HA, Abdelghaffar W, Labib AM, et al. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications[J]. Ophthalmology,2011,118(4):636-641. DOI:10.1016/j.ophtha.2010. 08.038.
[14]
Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy[J]. Br J Ophthalmol,2008,92(2):21321-6. DOI:10.1136/bjo.2007.127142.
[15]
Arevalo JF, Sanchez JG, Lasave AF, et al. Intravitreal bevacizumab (Avastin) for diabetic retinopathy: the 2010 GLADAOF lecture[J]. J Ophthalmol,2011,2011:584238. DOI:10. 1155/2011/584238.
[16]
Sultan MB, Zhou D, Loftus J, et al. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema[J]. Ophthalmology,2011,118(6):1107-1118. DOI:10.1016/j.ophtha.2011.02.045.
Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema[J]. Ophthalmology,2011,118(9):1819-1826. DOI:10.1016/j.ophtha.2011.02.018.
[19]
Vandekerckhove KR. Aflibercept versus ranibizumab for treating persistent diabetic macular oedema[J]. Int Ophthalmol,2015,35(4):603-609. DOI:10.1007/s10792-015-0081-7.
[20]
Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2[J]. Ophthalmology,2010,117(6):1078-1086.e2. DOI:10.1016/j.ophtha.2010.03.045.
[21]
Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3[J]. Arch Ophthalmol,2012,130(8):972-979. DOI:10.1001/archophthalmol.2012.393.
[22]
Hanhart J, Chowers I. Evaluation of the response to ranibizumab therapy following bevacizumab treatment failure in eyes with diabetic macular edema[J]. Case Rep Ophthalmol,2015, 6(1):44-50. DOI:10.1159/000375230.
[23]
Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study[J]. Ophthalmology,2009,116(11):2175-2181.e1. DOI:10.1016/j.ophtha.2009.04.023.
[24]
Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study[J]. Ophthalmology,2010,117(11):2146-2151. DOI: 10.1016/j.ophtha.2010.08.016.
[25]
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE[J]. Ophthalmology,2012,119(4):789-801. DOI:10.1016/j.ophtha.2011.12.039.
[26]
Ishibashi T, Li X, Koh A, et al. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in asian patients with diabetic macular edema[J]. Ophthalmology,2015,122(7):1402-1415. DOI:10.1016/j.ophtha.2015. 02.006.
[27]
Simha A, Braganza A, Abraham L, et al. Anti-vascular endothelial growth factor for neovascular glaucoma[J]. Cochrane Database Syst Rev,2013,10:CD007920. DOI:10.1002/14651858.CD007920.pub2.
[28]
Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases[J]. Ophthalmology,2008,115(9):1571-1580. DOI:10.1016/j.ophtha.2008.02.026.
[29]
Wolf A, von Jagow B, Ulbig M, et al. Intracameral injection of bevacizumab for the treatment of neovascular glaucoma[J]. Ophthalmologica,2011,226(2):51-56. DOI:10.1159/000327364.
[30]
Kahook MY. Bleb morphology, and vascularity aftertrabeculectomy with intravitreal ranibizumab: A pilot study[J]. Am J Ophthalmol,2010,150(3):399-403.e1. DOI:10.1016/j.ajo.2010.03.025.
[31]
Zhou M, Xu X, Zhang X, et al. Clinical outcomes of ahmed glaucoma valve implantation with or without intravitreal bevacizumab pretreatment for neovascular glaucoma: A Systematic Review and Meta-Analysis[J]. J Glaucoma,2016,25(7):551-557. DOI:10.1097/IJG.0000000000000241.
[32]
Li XJ, Yang XP, Li QM, et al. Ranibizumab plus combined surgery for treatment of neovascular glaucoma with vitreous hemorrhage[J]. Chin Med J (Engl),2015,128(15):2078-2083. DOI: 10.4103/0366-6999.161371.
[33]
Huang YH, Yeh PT, Chen MS, et al. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage[J]. Retina,2009, 29(8):1134-1140. DOI:10.1097/IAE.0b013e3181b094b7.
[34]
Sinawat S, Rattanapakorn T, Sanguansak T, et al. Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation[J]. Eye (Lond),2013,27(12):1391-1396. DOI:10.1038/eye.2013.200.
[35]
Jonas JB, Libondi T, von Baltz S, et al. Intravitreal bevacizumab for vitreous haemorrhage[J]. Acta ophthalmol,2008,86(5):585-586. DOI:10.1111/j.1600-0420.2007.01107.x.
[36]
Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy[J]. JAMA Ophthalmol,2013,131(3):283-293. DOI:10.1001/jamaophthalmol.2013.2015.
[37]
van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections[J]. Retina,2011,31(8):1449-1469. DOI:10.1097/IAE.0b013e3182278ab4.
[38]
Torres-Soriano ME, Reyna-Castelan E, Hernandez-Rojas M, et al. Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy[J]. Retin Cases Brief Rep,2009,3(1):70-73. DOI:10.1097/ICB.0b013e3181578dd8.
[39]
Yeh PT, Yang CM, Lin YC, et al. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy[J]. Retina,2009,29(6):768-774. DOI:10.1097/IAE.0b013e3181a3b7ef.
浙公网安备 33030202001892号